glycosphingolipids

Preferred Label : glycosphingolipids;

MeSH definition : Lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide (CERAMIDES). They are subdivided into NEUTRAL GLYCOSPHINGOLIPIDS comprising monoglycosyl- and oligoglycosylsphingoids and monoglycosyl- and oligoglycosylceramides; and ACIDIC GLYCOSPHINGOLIPIDS which comprises sialosylglycosylsphingolipids (GANGLIOSIDES); SULFOGLYCOSPHINGOLIPIDS (formerly known as sulfatides), glycuronoglycosphingolipids, and phospho- and phosphonoglycosphingolipids. (From IUPAC's webpage);

MeSH synonym : asialogangliosides; sphingoglycolipids; Glycosphingolipid; Sphingoglycolipid; Asialoganglioside;

Wikipedia link : https://en.wikipedia.org/wiki/Glycosphingolipid;

Is substance : O;

Details

Origin ID

D006028;

UMLS CUI

C0017978;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Glycosphingolipid [FMA entity]
- glycosphingolipid [IUPAC Term]
Indexing information
- stage-specific embryonic antigen-3 [MeSH Supplementary Concept]
- stage-specific embryonic antigen-4 [MeSH Supplementary Concept]
Record concept(s)
- glycosphingolipids [MeSH concept]
Related MeSH Supplementary Concept(s)
- (2S,3S,4R)-1-O- (alpha-D-galactosyl)-2- tetracosanoylamino-1,3,4-nonanetriol [MeSH Supplementary Concept]
- (3-deoxyxylohexopyranosyl)-1-4-(1-fucopyranosyl-1-3)-(2-deoxy-2-acetamidoglucopyranosyl)-1-3-galactopyranosyl-1-4-glucopyranosyl-(1-1)-2-octadecanamido-4-octadecene-1,3-diol [MeSH Supplementary Concept]
- (4-deoxyxylohexopyranosyl)-1-4-(1-fucopyranosyl-1-3)-(2-deoxy-2-acetamidoglucopyranosyl)-1-3-galactopyranosyl-1-4-glucopyranosyl-(1-1)-2-octadecanamido-4-octadecene-1,3-diol [MeSH Supplementary Concept]
- 1-(glucopyranosyl)-3-hydroxy-2-(2'-hydroxyheptadecanoyl)amino-9-methyl-4,8-octadecadiene [MeSH Supplementary Concept]
- 1-O-(2-N-stearoylsphinganine-1-phosphoryl)-2-O-(mannopyranosyl)inositol [MeSH Supplementary Concept]
- 2,3-disulfo-Le(x) pentaosylceramide [MeSH Supplementary Concept]
- 2-aminoethylphosphonylglycosphingolipid [MeSH Supplementary Concept]
- 2-deoxy-2-acetamido-D-glucopyranosyl(alpha 1-4)-D- glucuronopyranosyl(alpha 1-2)myoinositol-1-O- phosphoceramide [MeSH Supplementary Concept]
- 3-sulfo-Le(x) pentaosylceramide [MeSH Supplementary Concept]
- 9-O-methyl-(N-acetyl-alpha-D-neuraminosyl)-(2-3)-inositolphosphoceramide [MeSH Supplementary Concept]
- GL-Y [MeSH Supplementary Concept]
- GSC 150 [MeSH Supplementary Concept]
- HK1-ceramide 2 [MeSH Supplementary Concept]
- I-antigen [MeSH Supplementary Concept]
- KDN-lactotetraosylceramide [MeSH Supplementary Concept]
- KDN-neolactotetraosylceramide [MeSH Supplementary Concept]
- LPG2 protein, leishmania [MeSH Supplementary Concept]
- O-mannopyranosyl-(1-3)-O-mannopyranosyl-(1-4)-O-glucopyranosyl-(1-1)-2-N-tetracosanoylsphingenine [MeSH Supplementary Concept]
- O-mannopyranosyl-(1-3)-O-xylopyranosyl-(1-2)-O-mannopyranosyl-(1-4)-O-glucopyranosyl-(1-1)-2-N-tetracosanoylsphingenine [MeSH Supplementary Concept]
- PGL3a glycosphingolipid [MeSH Supplementary Concept]
- PGL3b glycosphingolipid [MeSH Supplementary Concept]
- Y glycolipid [MeSH Supplementary Concept]
- blood group A glycolipid A-6-2 [MeSH Supplementary Concept]
- catacerebroside A [MeSH Supplementary Concept]
- catacerebroside B [MeSH Supplementary Concept]
- catacerebroside C [MeSH Supplementary Concept]
- ceramide 3 [MeSH Supplementary Concept]
- ceramide bis(2-aminoethylphosphono)pentaoside [MeSH Supplementary Concept]
- ceramide digalactoside [MeSH Supplementary Concept]
- ceramide dihexoside [MeSH Supplementary Concept]
- ceramide heptassaccharide [MeSH Supplementary Concept]
- ceramide mono(2-aminoethylphosphono)pentaoside [MeSH Supplementary Concept]
- ceramide pentasaccharide [MeSH Supplementary Concept]
- ceramide trihexoside [MeSH Supplementary Concept]
- cytolipin S [MeSH Supplementary Concept]
- di(inositolphosphoryl)ceramide [MeSH Supplementary Concept]
- difucosyl heptaglycosylceramide [MeSH Supplementary Concept]
- difucosylneolactonorhexaosylceramide [MeSH Supplementary Concept]
- digalactosyl ceramide [MeSH Supplementary Concept]
- dihexosylceramide [MeSH Supplementary Concept]
- diphosphonopentaosylceramide [MeSH Supplementary Concept]
- euojaposphingoside A [MeSH Supplementary Concept]
- euojaposphingoside B [MeSH Supplementary Concept]
- euojaposphingoside C [MeSH Supplementary Concept]
- flavuside A [MeSH Supplementary Concept]
- flavuside B [MeSH Supplementary Concept]
- fucosylneolactonorhexaosylceramide [MeSH Supplementary Concept]
- fucosyltetrahexosylceramide [MeSH Supplementary Concept]
- glycosphingolipid GSL-1 [MeSH Supplementary Concept]
- glycosphingolipid GSL-3 [MeSH Supplementary Concept]
- inositolphosphoceramides [MeSH Supplementary Concept]
- inositolphosphorylceramide [MeSH Supplementary Concept]
- lacto-N-norhexosylceramide [MeSH Supplementary Concept]
- lactotetraosylceramide [MeSH Supplementary Concept]
- le(b)-active glycolipid [MeSH Supplementary Concept]
- le(y)-active trifucosylnonaosylceramide [MeSH Supplementary Concept]
- lipid III [MeSH Supplementary Concept]
- lipophosphonoglycan [MeSH Supplementary Concept]
- mannose-bis(inositolphospho)ceramide [MeSH Supplementary Concept]
- mannosyl-1-4-(fucosyl-1-3)glucosyl-1-ceramide [MeSH Supplementary Concept]
- mannosylinositol phosphoylceramide [MeSH Supplementary Concept]
- mannosylinositolphosphoceramide [MeSH Supplementary Concept]
- neurosporaside [MeSH Supplementary Concept]
- neurostatin [MeSH Supplementary Concept]
- panajaponin [MeSH Supplementary Concept]
- rhizochalin A [MeSH Supplementary Concept]
- rhizochalin C [MeSH Supplementary Concept]
- rhizochalin D [MeSH Supplementary Concept]
- sialyl 2-1 sphingosine [MeSH Supplementary Concept]
- sulfated le(a) pentaosylceramide [MeSH Supplementary Concept]
- sulfogangliotetraosylceramide IV(3) [MeSH Supplementary Concept]
- sulfoglycolipid A [MeSH Supplementary Concept]
- sulfoglycolipid P [MeSH Supplementary Concept]
- trifucosyl-Lewis-b antigen [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Glycosphingolipid [FMA entity]
Validated automatic mappings to NTBT
- Glycolipid (substance) [SNOMED CT concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients